Fundraising Fox

Precede

Boston, US · Founded 2021 · 65 employees on LinkedIn · 12 known investors

Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials. The platform enables non-invasive patient selection and longitudinal tracking of disease mechanisms in oncology and other therapeutic areas.

AI & Machine LearningBiotechDigital Health

Founders & leadership

Precede was founded in 2021 by Rehan Verjee, Sylvan Baca, Toni Choueiri, and Matthew Freedman.

RVRehan Verjee
Rehan VerjeeCo-Founder, Chief Executive Officer, Board Director
SB
Sylvan BacaCo-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute
TC
Toni ChoueiriCo-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute
MF
Matthew FreedmanCo-Founder; Professor of Medicine, Dana-Farber Cancer Institute

Investors · 12

Illumina Ventures✓ verifiedFoster City
5AM Ventures✓ verifiedBoston · $100K – $4M
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Lilly Asia VenturesreportedHong Kong
Osage University PartnersreportedBala Cynwyd

Also in the syndicate · 7

28 CapitalBinney Street CapitalBristol Myers SquibbLabcorp Venture FundMirae Asset CapitalMirae Asset Capital Life ScienceUPMC Enterprises

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 3

by search overlap
Precision BioSciences51 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Labcorp30 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
IQVIA27 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.

Companies competing with Precede for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Precede Biosciences Raises $83.5M in Financing | citybizcitybiz.co · Jan 2026Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform - BioSpacebiospace.com · Jan 2026Medpathtrial.medpath.com · Jan 2026Precede Biosciences Emerges From Stealth With $57M in Fundingfinsmes.com · Oct 2023Who We Are - Precede Capital Partnersprecedecapital.com · Jan 2021

Frequently asked questions

What does Precede do?
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials. The platform enables non-invasive patient selection and longitudinal tracking of disease mechanisms in oncology and other therapeutic areas.
Who founded Precede?
Precede was founded by Rehan Verjee, Sylvan Baca, Toni Choueiri, Matthew Freedman in 2021.
Who are Precede's investors?
Precede's investors include Illumina Ventures, 5AM Ventures, OUP (Osage University Partners), Lilly Asia Ventures, Osage University Partners.
Where is Precede headquartered?
Precede is headquartered in Boston, US.